Trial Profile
ALK33-001: A Phase 1 Study of the Pharmacokinetics of RDC-0313 Administered to Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Samidorphan (Primary)
- Indications CNS disorders; Substance-related disorders
- Focus Pharmacokinetics
- Sponsors Alkermes plc
- 29 Oct 2014 New trial record